Showing 1,510 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Gilead's $1.5B in remdesivir sales help buoy worse-than-expected declines for mainstay HIV, hepatitis C drugs

Editor's pick
FiercePharma
4 May 2021
Access to healthcare

Big drops in the cost of antiretroviral medicines, but COVID-19 threatens further reductions

Editor's pick
UNAIDS
4 May 2021
PrEP policies & guidelines

Preventing HIV Just Got A Lot Cheaper. What Took So Long?

Editor's pick
Tradeoffs (podcast)
28 April 2021
Pharmaceutical industry

Clinical Trial Data Needs to Reflect the Demographics of HIV, Say Activists

Editor's pick
TheBodyPro
12 April 2021
People & personal stories

Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep C drugs, has died

Editor's pick
FiercePharma
1 April 2021
Finance & funding

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

News
15 March 2021
Injectable & long-acting HIV treatment

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Editor's pick
Gilead press release
15 March 2021
PrEP programmes & uptake

Large numbers now on Descovy PrEP in the United States

News
9 March 2021
PrEP programmes & uptake

PrEP Shortages Hit Pharmacies in Sydney, Melbourne

Editor's pick
Star Observer
16 February 2021
Pharmaceutical industry

Ireland: Gilead loses patent suit to stop generic HIV drug

Editor's pick
The Irish Times
3 February 2021
The search for a cure

Gilead Sciences pens early-stage HIV vaccine pact with Gritstone Oncology

Editor's pick
FierceBiotech
1 February 2021
Injectable & long-acting HIV treatment

FDA approves first long-acting injectable to treat HIV infection

Editor's pick
STAT
22 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment

Editor's pick
ViiV Healthcare press release
22 January 2021
Pharmaceutical industry

New Twist in the Gilead Patent Lawsuit Over Truvada and Descovy to Prevent HIV

Editor's pick
POZ
8 January 2021
Pharmaceutical industry

Counterfeit HIV Med Symtuza Found in Three U.S. Pharmacies

Editor's pick
POZ
3 January 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

Editor's pick
ViiV Healthcare press release
21 December 2020
Access to healthcare

Cheaper HIV treatment for children

Editor's pick
The Lancet (free registration required)
11 December 2020
New & experimental HIV treatments

ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available

Editor's pick
ViiV Healthcare press release
11 December 2020
Access to healthcare

New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency

Editor's pick
Health GAP (Global Access Project)
8 December 2020
PrEP policies & guidelines

HIV prevention drugs illustrate just how bad pharmaceutical patents are for our health

Editor's pick
NBC News
3 December 2020
Combatting stigma

ViiV Healthcare and Shutterstock Studios unite to tackle outdated perceptions of HIV with ‘HIV in View’ - a first-of-its-kind online HIV photography gallery

Editor's pick
ViiV Healthcare press release
1 December 2020
New & experimental HIV treatments

Data sets up 2021 filings for Gilead's twice-a-year HIV drug lenacapavir

Editor's pick
Pharmaphorum
20 November 2020
New & experimental HIV treatments

Gilead Announces Investigational Long-Acting HIV-1 Capsid Inhibitor, Lenacapavir, Achieves Primary Endpoint in Phase 2/3 Study in Heavily Treatment-Experienced People Living With HIV

Editor's pick
Gilead press release
20 November 2020
Injectable & long-acting PrEP

ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention

Editor's pick
ViiV press release
17 November 2020